Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EuroNet-Paediatric Hodgkin’s Lymphoma Group Phase 3 Study
2006-000995-33Phase 3Completed
- Sponsor
- Martin-Luther-University Halle-Wittenberg
- Start
- Sep 2006
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of doxorubicin, etoposide, vincristine, vinblastine, cyclophosphamide and 8 more in classical Hodgkin lymphoma (cHL), sponsored by Martin-Luther-University Halle-Wittenberg. Primary endpoints: Event-free survival (primary) and Event-free survival in inadequate responders (primary). Started Sep 2006; status: completed.
02
Drugs
doxorubicinetoposidevincristinevinblastinecyclophosphamide
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2006-000995-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000995-33.